CU Logo University of Colorado Anschutz Medical Campus
Your search for "Genetics/Personalized Health" found 17 matches:
CU-GENES (Genetic Engagement, Education, and Screening)

Inclusion Criteria: • Over the age of 25 • At least one grandparent of Jewish ancestry OR be of Spanish ancestry with roots in the San Luis Valley • No prior genetic testing • No personal history of bone marrow transplants or blood cancers • Currently live in Colorado OR New Mexico ...
An Operationally Seamless, Randomized Phase 2/3 Study Consisting of a Phase 2 Single-Blind, Dose-Evaluation Phase and a Phase 3 Double-Blind, Placebo-controlled Phase to Assess the Efficacy and Safety of Setrusumab in Subjects with Osteogenesis Imperfecta

Childrens Hospital Colorado

A clinical trial examining the efficacy of Setrusumab in reducing fractures compared to a placebo for patients with Osteogenesis Imperfecta....
MECHANISTIC INVESTIGATION OF THERAPIES FOR DOWN SYNDROME REGRESSION DISORDER

Childrens Hospital Colorado

Individuals with Down syndrome (DS) have an increased risk of numerous co-occurring conditions, including the neuropsychiatric condition known as Down Syndrome Regression Disorder (DSRD). A DSRD diagnosis often includes a sub-acute onset of catatonia, mutism, depersonalization, loss of abi...
Human Trisome Project

Childrens Hospital Colorado, Outpatient CTRC, Outpatient CTRC, University of Colorado Hospital

Additional information about this study can be found at www.trisome.org....
Safety and efficacy of tofacitinib for immune skin conditions in Down syndrome

Childrens Hospital Colorado, Outpatient CTRC, Outpatient CTRC, University of Colorado Hospital

This study is designed to determine whether tofacitinib is a safe and effective treatment for immune skin conditions in adults with Down syndrome, and to further our understanding of the immune system in Down syndrome. This is a single arm, open-label study. All participants will receiv...
Executive Functioning Outcome Measures for Down Syndrome

Childrens Hospital Colorado
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Childrens Hospital Colorado
Inspiring New Science in Guiding Healthcare in Turner Syndrome (INSIGHTS) Registry

Ann & Robert H. Lurie Children's Hospital of Chicago, Childrens Hospital Colorado, Childrens Hospital of Philadelphia, Childrens National Medical Center, University of North Carolina Children's Hospital, University of Texas Health Science Center at Houston

Participants who join the INSIGHTS Registry are agreeing to have their medical records be used for research. There are no additional study visits, etc. – participants just continue with their usual clinical care. In addition to the basic registry, individuals can join a recruitment list f...
MicroRNA as a Maternal and Neonatal Biomarker to Predict Congenital Diaphragmatic Hernia Severity

Childrens Hospital Colorado, University of Colorado Hospital
Multicentric Carpotarsal Osteolysis (MCTO): Natural History Study

Childrens Hospital Colorado
Identifying novel therapeutic targets in MCTO by unbiased proteomics of patient plasma

Childrens Hospital Colorado, Department Specific Free Standing Clinic
GALAXY: Generating Advancements through Longitudinal Analysis in X and Y Syndromes

Childrens Hospital Colorado, Outpatient CTRC

Participants who join the GALAXY Registry are agreeing to have their medical records be used for research. There are no additional study visits, etc. – participants just continue with their usual clinical care. If participants are seen outside of Children’s Colorado, they can sign a Releas...
Prospective Clinical Assessment Study in Children with Achondroplasia: The PROPEL Trial

Childrens Hospital Colorado
An Open-label, Randomized, Active-Controlled, Phase 3 Study of Setrusumab Compared With Bisphosphonates in Pediatric Subjects 2 to < 5 Years of Age With Osteogenesis Imperfecta Types I, III or IV

Childrens Hospital Colorado
AttaCH: A Phase 2, Multicenter, Long-Term, Open Label Extension Trial Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of TransCon CNP Administered Once Weekly in Children and Adolescents with Achondroplasia

Childrens Hospital Colorado
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Infigratinib in Children 3 to <18 Years of Age with Achondroplasia: PROPEL 3

Childrens Hospital Colorado
Achondroplasia Biobank

Childrens Hospital Colorado

Collecting a biological sample such as blood, saliva and/or buccal swab from the patients with achondroplasia and their family members...